Patent Application
20230083570
The present disclosure pertains generally to the acceleration of the decay rate of any isotope, and, in at least one exemplary embodiment, to the use of lasers to accelerate the decay of a selected isotope for the production of desired product isotopes. In at least one aspect, this disclosure outlines configurations of a system with a number of unique features to achieve isotope production.
Various isotopes have proven to be valuable and useful, for example, in applications in the healthcare, engineering/industrial, energy and space power fields. As an example, within healthcare, multiple isotopes are constituent ingredients in pharmaceuticals, including those used for imaging and therapeutic purposes. The production and supply of isotopes for these and other applications are limited by and although research to increase availability and reduce costs for users has been pursued, options remain limited. For example, the US Department of Energy's NIDC (National Isotope Development Center) coordinates efforts across multiple nuclear laboratories to provide several of these industries with a range of isotopes.
In one aspect, the present disclosure utilizes a method for accelerating the rate of decay of a targeted isotope, in at least one exemplary application, for the purpose of increasing the production rate of daughter isotopes that are formed from the target isotope's decay.
This exemplary approach induces and accelerates nuclear excitations at achievable peak laser intensity levels. The laser beam interacts with conductive nanoparticles and/or nanostructures in close proximity of the targeted atoms. This interaction causes resonance conditions of the charge carriers in the nanoparticles or nanostructures, which can enhance the field intensity by factors of 106-108. These substantial field increases in the laser radiation reach levels required to induce nuclear activity in the atoms exposed to these fields. In the present disclosure, this methodology is discussed and applied for the purpose of producing radioisotopes. In at least one exemplary embodiment, this configuration enables effective, scalable production of various isotopes.
This accelerated decay method can be combined with known radiochemical separation processes to separate and isolate desirable, high-value isotopes from the by-products of the accelerated decay process. Radioisotopes produced with this method can be used in fields including, but not limited to, pharmaceuticals, medical imaging and therapy, energy production, industrial sensors and military applications.
In at least one aspect, exemplary embodiments of the present disclosure pertain to systems, apparatus, and methodologies for producing various isotopes. The isotope production in at least one aspect of the present disclosure is enabled by using a laser system to irradiate target isotopes, the raw materials in this process, in the presence of conductive nanoparticles. The function of the nanoparticles is described in more detail below. In these exemplary embodiments, specific target isotopes (also sometimes referred to as parent isotopes) are irradiated to produce desired product isotopes (also sometime referred to as daughter isotopes), the steps of this exemplary process are laid out in
Through this exemplary method of laser irradiation in the presence of conductive nanoparticles, the natural decay rate of the target isotope is temporarily accelerated, transmuting atoms of the target isotope into atoms of the desired daughter isotopes. The resulting solution after the irradiation contains a mixture of elements including a fraction of the target isotope that has not transmuted, a fraction of the desired product isotope and fractions of other by-product isotopes. Following this process, known methods of chemical separation can be used to separate and purify desired products from the mixture of isotopes left after laser irradiation.
In at least one aspect of the present disclosure, accelerating the decay of target isotopes is used as a method of producing desired daughter isotopes, as described above. Accelerated decay is achieved by exposing the target isotopes to an electric field of an intensity large enough to induce nuclear excitations, increasing the probability and rate of nuclear decay. In the present disclosure, these electric fields are generated using a high intensity laser beam which interacts with specifically selected nanoparticles to cause Surface Plasmon Resonance (SPR), which is a scientific phenomenon that arises when light photons travel across the surface of a conducting material (e.g., gold, platinum and other materials) and induce oscillations in the electrons (charge carriers) within the conducting material. The oscillation of these electrons produces large electric fields near the surface of the material that can have intensities 106-108 times greater than the intensity of the laser. SPR is a phenomenon utilized extensively in fields, such as biomedical research.
In at least one aspect, the basis for SPR is described and graphically illustrated in
SPR was originally observed in solid or layered conductive materials. The advent of metallic nanoparticle fabrication has added the potential of creating resonance conditions in conductive nanoparticles exposed to a photon beam such as a laser. This advancement enables the generation of the SPR phenomenon using conductive nanoparticles in suspension within a solution of target isotopes. This configuration ensures that when the target isotopes in solution are close enough to the nanoparticles to experience the intense electric fields generated by the SPR phenomenon and induce nuclear excitations.
However, in order to create the resonant conditions of SPR, the laser wavelength must be matched to the nanoparticle size and material. The relationship between these parameters and their suitability to create resonant conditions for SPR are documented and represented in a field known as Mie Theory, aiding laser and nanoparticle selection in embodiments of the present disclosure.
An exemplary physical configuration of the present disclosure is represented in
A laser: The laser is used as the input of energy and power into the system and drives the process downstream nuclear excitations. Laser intensity (power over per unit area) is a key factor in the selection of the laser to use. To drive the process, in at least one exemplary embodiment, a field intensity of >108 W/cm2 is required. This intensity can be achieved directly with the laser system, where the beam intensity is calculated from the beam area (cm2), pulse energy (Joules) and pulse duration (seconds). If a focusing lens is used, then the beam intensity calculated should take into account the impact of the focusing on the intensity at the focal point of the lens can achieve intensities of >108 W/cm2 at the focal point while using a laser where the intensity is <108 W/cm2 before the lens. Thus, laser selection and the use of a lens primarily aims to maximize intensity (power per unit area, e.g., W/cm2) while also maximizing the area (cm2) experiencing the high intensity.
Laser wavelength is another factor in laser selection, viable wavelengths may cover the UV (100 nm-360 nm), visible (360 nm-830 nm), and IR (830 nm-1 mm) bands. Laser wavelength is coupled to nanoparticle size and material according to Mie Theory to ensure the occurrence of the SPR effect, as described above. For many of the laser wavelengths in these ranges there are suitable nanoparticles with specific size and material that will generate the SPR effect and so could be used in an exemplary embodiment of the present disclosure.
When selecting a laser for the system both pulsed lasers and continuous wave lasers can be considered as the laser source for the radioisotope generator. Pulsed lasers require a power density (W/cm2) of >108 W/cm2 as stated above, or a lens is used to achieve this intensity. Similarly, continuous wave (CW) lasers are also suitable if their total energy deposition is commensurate with the levels of the pulsed laser.
Optics: The laser source described above will produce a straight beam of light as common with lasers. This beam is then directed to the target using optics, such as mirrors, to achieve the desired direction and angle to hit the target.
In one exemplary embodiment, the beam may not use optics to divert and redirect the beam, but would be fired directly through the wall of the vial into the solution. This approach is viable so long as the vial material is selected to ensure that the laser beam does not damage or break the vial.
In another exemplary embodiment, the beam is directed using three separate mirrors so that the beam is firing vertically down into the vial or vessel carrying the target solution. This particular exemplary optical arrangement is graphically represented in
In another exemplary embodiment, a galvo scanner is used to manipulate the beam to move in a controlled way to fire into the target at different locations. A galvo scanner is optical equipment that moves a mirror at a set speed and angle so that the laser beam is rapidly redirected. This exemplary embodiment using a galvo scanner enables the use of increased repetition rates to fire the beam into a larger area of the target solution over the run time of the laser irradiation.
In the exemplary embodiments, the arrangement aims to ensure that the laser is fired into the solution with minimal obstruction and that the equipment and apparatus are not damaged by the laser.
As mentioned above, the laser beam may also be directed through a selected lens to increase power density at a focal point or to divert the laser output in a specific direction onto the target. The lens may or may not be necessary to achieve the desired power density as lasers with suitable characteristics without an external lens may forego this component. These optics (e.g., mirrors, galvo scanners, lenses) can be independent of the laser and the vial/container or integrated into the laser head or container.
Vial/vessel: The purpose of the vial or vessel is to safely contain the target and nanoparticle mixture during irradiation and for transport into and out of the irradiation location. There are a vast number of embodiments and variations of container that can carry the mixed target solution and nanoparticles. Factors such as heat resistance, depth, handling convenience, seal etc. may be considered to improve the operational ease and safety of the apparatus.
In the exemplary embodiment of
The vial/vessel may include reflective, refractive, or other beam influencing components, included but not limited to: concave/convex mirrors, blackbody cavity assembly, resonance chamber assembly, spigots or spouts to account for splashing or evaporation, mixers, shakers, and other mechanisms to ensure a consistent mixture of the solution.
Target isotope solution—In one exemplary embodiment, target isotope material is dissolved into solution with an acid, such as nitric acid. Water or various acids can be used to create the solutions and may be selected based on the properties that they hold for efficient chemical separation after irradiation.
Creating this liquid solution also provides a medium in which to mix the selected nanoparticles, mentioned above. This exemplary method ensures that volumes of the target isotope are in close proximity to the nanoparticles, and close to enough, within 100nm, to experience the fields generated by SPR. In a liquid or medium the target isotope may be stirred or mixed to keep the nanoparticles and isotope atoms in close proximity.
Methods to include the target isotope without dissolving may include suspending it in a solid transparent matrix such as sapphire, glass, quartz, alumina, diamond, or other material assuming the geometry and components are able to maintain the necessary positions and distributions.
Nanoparticles in suspension in the target isotope solution: Nanoparticles of different materials, including gold, platinum, silicon, silicon dioxide, silver, aluminum, nickel, copper, CuO, TiO2, and cobalt can be appropriate to create the desired SPR effect when interacting with the laser beam. The specific material and size selected should be commensurate with Mie Theory to produce the resonating conditions and electric fields of SPR as stated above.
Nanoparticle density in the solution can be varied to optimize intensity, extinction length and interaction counts. These factors will influence total isotope production in a given period or irradiation. Nanoparticle densities or concentrations in the range of 0.001 milligrams per milliliter up to 10 milligrams per milliliter of target isotope solution have been shown to produce the SPR effect and can induce and accelerate decay in the surrounding target isotopes.
Exemplary Description of the Method of the Present Disclosure
One exemplary process is shown at a high level in
As mentioned above, the present radioisotope generator can produce isotopes which are useful in fields including pharmaceuticals, medical imaging and therapy, energy production, industrial sensors and military applications.
One exemplary application of the present disclosure involves production of isotopes for use in pharmaceuticals for cancer therapy. The radioisotope generator described herein can be used, for example, for the production of the isotope Actinium-225, which is an input ingredient in a form of cancer therapy called Targeted Alpha Therapy. Generally, other production routes for Actinium-225 are a by-product of nuclear fission in a nuclear reactor. In at least one exemplary embodiment, the present disclosure can be used as a fundamentally new approach to producing Ac-225. The following target isotopes could be used to produce Actinium-225: Neptunium-237, Uranium-233, Thorium-229, Radium-225.
As mentioned above, inducing and accelerating decay of a target isotope will result in a mixture of isotopes after the laser irradiation that could include a fraction of the target isotope that has not transmuted, a fraction of the desired product isotope and fractions of other by-product isotopes. Following this process, known methods of chemical separation can be used to separate and purify desired products from the mixture of isotopes left after laser irradiation. In one exemplary process, where Uranium-233 is used as the target isotope, the resulting mixture may include fractions of isotopes including Uranium-233, Thorium-228, Radium-225 and Actinium-225. This mixture can then be separated using known chemical separation methods to achieve various levels of concentration of the Actinium-225 product suitable for supply to pharmaceutical companies.
Examples of target isotopes and the associated product isotopes which are known to be of value are shown in
In at least one aspect of the present disclosure, the radioisotope generator system induces and accelerates decay of target isotopes to produce quantities of daughter isotopes. This process has two additional obvious additional applications which are being developed include:
(1) The transmutation of unwanted target isotopes by accelerated radioactive decay. The decay of highly radioactive waste materials of various isotopes can be accelerated, releasing energy from these isotopes and transmuting them towards stability. These stable daughter products are less hazardous as they are less radioactive. In at least one exemplary embodiment of the present disclosure this system could process nuclear waste from nuclear fission or fusion plants.
(2) The release of energy from the target isotopes in the form of radioactive decay. The induced and accelerated decay process also releases substantial energy from the target isotope. This energy can be captured for conversion into heat and/or electricity utilizing common thermal power generation equipment such as a steam turbine or a thermocouple. In at least one exemplary embodiment of the present disclosure this system could be used to generate usable electric power.
For exemplary purposes only and without limiting the foregoing, the following exemplary definitions are provided generally:
In one exemplary embodiment, processes intended for use with a radioisotope generator are detailed. Among other things, methods of inducing and/or accelerating the decay of radioisotopes to produce other radioisotopes using laser interactions with nanoparticles suspended in a solution of isotopes are detailed, including a process to remove the radioisotopes from the nanoparticle solution. In one exemplary aspect, the exemplary embodiment provides a process utilizing a solution containing:
Nanoparticles
Parent isotopes
Isotopes of interest to be decayed
A liquid, solid, or gaseous medium (hereafter referred to as the “solution”). The solution is processed to extract the isotopes of interest without damaging or consuming the other components. To achieve this, the process describes:
Chemical separation of some or all of the components listed above
Physical separation of some or all of the components listed above
Return to the original state of the solution
One exemplary aspect of the process includes:
Another exemplary embodiment is described as including a solution of nitric acid containing dissolved uranium nitrate, 20 nm gold nanoparticles, and Thorium-229 which has been generated from the parent Uranium isotope using, for example, a radioisotope generator process detailed above. The target is emptied into a centrifuge and spun to distribute the nanoparticles along the outer edges of the container (mechanical separation). The liquid solution is then extracted via pipette and placed in a mixer to adjust the pH, chemical makeup, or other aspects as necessary according to available protocols. The solution is then transferred to a chromatography column, wherein the Thorium-229 isotope is extracted. The solution is then transferred to a chromatography column to extract the uranium nitrate. The nanoparticles and uranium nitrate are then added to a new solution including of, generally fresh, nitric acid and once again used in the radioisotope generator.
Other exemplary embodiments can include different parent isotopes, such as:
Other exemplary embodiments can include different liquid, solid, or gaseous media, including but not limited to:
In yet another exemplary embodiment, a vial or vessel is detailed that includes an exemplary design of a container for target materials. Alternative exemplary designs of the vial or vessel (hereafter referred to as the “target), which, in one aspect, are intended to contain the nanoparticle solution and target isotope are provided. Additional exemplary designs provide further capabilities of the target to:
In one exemplary embodiment, an exemplary process includes four components:
In one aspect, an exemplary embodiment shown in
Another embodiment is shown in
In yet another exemplary embodiment, additional uses of the generated product isotopes, including, for example, a specific use the radioisotope generator for electrical power production.
Radioisotopes generated in a radioisotope generator can be gathered and allowed to generate further decay heat for power generation, similar in fashion to a radioisotope thermoelectric generator or Stirling radioisotope generator. Production, including mass production, of radioisotopes for this power generation using a radioisotope generator are provided.
Additionally, the radioisotope generator can be used to actively produce power by harnessing the energy released during the induced decay process. Alpha decay, for example, releases ˜2-5 MeV per decay, which will be deposited into the target solution. This energy can be captured and converted to power during radioisotope generator operation.
In one exemplary process of harnessing energy, a fluorescing medium may be added to the target to generate light when interacting with ionizing radiation. As the alpha particle passes by a fluorescing molecule, it will excite electrons and cause the molecule to generate light, with the light able to be captured, e.g., with a photovoltaic cell, to generate electrical power.
Additionally, if the wavelength of generated light is similar to that of the laser used in the RADIOISOTOPE GENERATOR, it may contribute to further Surface Plasmon Resonance (SPR) events which induce further radioisotope decay in surrounding atoms. For certain configurations, this would result in an assembly where a single laser firing could cause a chain reaction in the target as fluorescing molecules create more SPR events and trigger more fluorescence.
This exemplary process is similar in nature to the criticality of a nuclear fission reactor, where each fission must create exactly one other fission on average to reach criticality, or cause more than one fission on average to reach supercriticality. In the case of the fluorescent chain reaction, each decay caused by SPR could create exactly one other decay by SPR to achieve criticality, and more than one other decay by SPR to reach supercriticality.
A critical photonic assembly as described herein could be used to provide energy to PV cells for electric power, create a source of light with very long lifetimes, or for a supercritical assembly could be used for weapons, explosives, or demolition.
Further still, the heat generated by the decay of the radioisotopes could also be captured in the surrounding medium of the target and used to turn a turbine, or simply used to expand a gas in a Brayton cycle.
Thus, the isotopes generated by the radioisotope generator can be used for power generation, in a process with a fluorescing medium to generate light, in a process with a fluorescing medium to generate light which is then used to generate more SPR events, and/or to run a power cycle during the accelerated decay process.
In yet another exemplary embodiment, processes intended for use with a radioisotope generator are detailed. Among other things, methods of inducing and/or accelerating the decay of radioisotopes to produce other radioisotopes using laser interactions with nanoparticles suspended in a solution of isotopes are detailed, including additional uses of the generated products. These exemplary uses, include, for example, using the radioisotope generator for the production of isotopes for pharmaceutical use.
Radioisotopes generated in the radioisotope generator can be gathered and used for targeted alpha therapy, targeted beta therapy, diagnostics, radiotherapy, or other medical uses.
Targeted alpha therapy is used by attaching an alpha emitter to a molecule which preferentially attaches itself to areas of interest, such as cancer cells. The alpha emitter attached to the molecule eventually decays, and the decay products (e.g., an alpha particle) damage the target area. Often, the alpha particle is capable of breaking both strands of the double helix of DNA, which is very effective at killing cells. Examples of radioisotopes used in targeted alpha therapy include Ac-225 and Pb-212.
Targeted beta therapy also takes place when a radioisotope is attached to a site specific molecule, but the decay process is beta instead of alpha. The beta particle usually travels a longer distance than the alpha particle and does not often cause double breaks in DNA strands. Thus, the targeted beta therapy is usually not as effective as the targeted alpha therapy. However, in certain cases it is still used. An example of a targeted beta therapy isotope is Lu-177.
Isotopes can be used in diagnostics by emitting radiation which can be traced even when within the body. Certain organs or areas may gather elements or molecules, and as those particles decay, the radiation signature can be read. An example of diagnostic radioisotope is Tc-99m.
Radiotherapy takes place when radiation is used to directly damage hostile tissue. This is often performed with x-ray or gamma radiation from an external source. However, isotopes created by the diagnostics radioisotope generator can be inserted directly into a patient, or used as a gamma/x-ray source externally as well. An example of a gamma emitting radioisotope is Co-60.
As the isotopes used in pharmaceutical applications are prone to decay, they may need to be continuously generated. One method of creating the useful isotopes which often do not exist for long periods of time, is to create an isotope “cow” comprised of a parent isotope which, through the natural nuclear decay process, supplies the useful isotope in question. Examples of this may be a Th-229 cow which constantly produces Ac-225 as it decays, or Mo-99 which produces Tc-99m as it decays. In an exemplary embodiment, the radioisotope generator can also be used to make these “cows” for the purpose of then eluting from them their daughter products used in various pharmaceutical applications, as described.
Thus, the isotopes generated by the radioisotope generator can be used for targeted alpha therapy, for targeted beta therapy, for medical diagnostics, for radiotherapy, or for making cows (also known as isotope generators) of other isotopes used in the pharmaceutical industry.
In at least one exemplary embodiment, a radioisotope generator comprises a laser, a volume of a target isotope in a solid or liquid solution state, nanoparticles or nanostructures in a solid, liquid or gas state, and a mixer for mixing the volume. In at least one embodiment, the laser is operated within the wavelength range of 400 nm-2500 nm. In at least one embodiment, the target isotope is one of: Uranium-233; Uranium-235; Uranium-238; Thorium-228; Thorium-229; Thorium-232; Americium-241; Neptunium-237. In at least one embodiment, the nanoparticles are in a solution with concentrations ranging from 0.001 milligrams per milliliter up to 10 milligrams per milliliter. In at least one embodiment, the nanoparticles or nanostructures are made of a single element or mixtures of elements including: gold, platinum, silicon, silicon dioxide, silver, aluminum, nickel, copper, CuO, TiO2, and cobalt. In at least one embodiment, the mixer enables flow of the volume, mixing of the volume, or both the flow of the volume and the mixing of the volume. In at least one embodiment, the mixer is a spinning blade, air pressure, or both the spinning blade and the air pressure to limit vapors and ejecta leaving the volume. In at least one embodiment, the intensity (power per unit area) of the laser is above 108 W/cm2 (Watts per square centimeter). In at least one embodiment, the intensity (power per unit area) of the laser beam is increased above 108 W/cm2 using optics such as lenses.
In at least one embodiment, a method of producing an isotope comprises providing a radioisotope generator that comprises a laser, a volume of a target isotope in a solid or liquid solution state, and nanoparticles or nanostructures in a solid, liquid, or gas state, operating the laser at 100 nm to 1 mm wavelength to produce a daughter isotope from the target isotope, and mixing the volume. In at least one embodiment, the method further comprises using the daughter isotope in pharmaceutical applications including: imaging; targeted alpha therapy; targeted beta therapy; isotope generators (also known as “cows”). In at least one embodiment, the method further comprises selecting target parent isotopes which decay into the daughter isotope used in Radioisotope Thermo-electric Generators (RTGs). In at least one embodiment, the method further comprises converting the radiation and/or heat released in the decay process to usable energy by thermal power generation, photovoltaic methods, or a critical photonic assembly. In at least one embodiment, the method is used to produce isotopes for use in industrial and scientific applications by selecting target parent isotopes which decay into daughter product isotopes used in non-medical applications. In at least one embodiment, the method further comprises transmuting hazardous, radioactive nuclear waste into stable, less hazardous waste using the radioisotope generator with the radioactive material as a target isotope; and producing daughter isotopes. In at least one embodiment, the method further comprises chemically, mechanically, or chemically and mechanically separating and extracting nanoparticles and various target and product isotopes from the volume.
In the drawings, like numerals indicate like elements throughout. Certain terminology is used herein for convenience only and is not to be taken as a limitation on the present disclosure. The terminology includes the words specifically mentioned, derivatives thereof and words of similar import. The embodiments illustrated below are not intended to be exhaustive or to limit the disclosure to the precise form disclosed. These embodiments are chosen and described to best explain the principle of the disclosure and its application and practical use and to enable others skilled in the art to best utilize the disclosure.
The present disclosure can be understood more readily by reference to the instant detailed description, examples, and claims. It is to be understood that this disclosure is not limited to the specific systems, devices, and/or methods disclosed unless otherwise specified, as such can, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular aspects only and is not intended to be limiting.
The instant description of the disclosure is provided as an enabling teaching of the disclosure in its best, currently known aspect. Those skilled in the relevant art will recognize that many changes can be made to the aspects described, while still obtaining the beneficial results of the present disclosure. It will also be apparent that some of the desired benefits of the present disclosure can be obtained by selecting some of the features of the present disclosure without utilizing other features. Accordingly, those who work in the art will recognize that many modifications and adaptations to the present disclosure are possible and can even be desirable in certain circumstances and are a part of the present disclosure. Thus, the instant description is provided as illustrative of the principles of the present disclosure and not in limitation thereof.
As used herein, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to a “body” includes aspects having two or more bodies unless the context clearly indicates otherwise.
Ranges can be expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, another aspect includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms another aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint.
As used herein, the terms “optional” or “optionally” mean that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.
Although several aspects of the invention have been disclosed in the foregoing specification, it is understood by those skilled in the art that many modifications and other aspects of the disclosure will come to mind to which the disclosure pertains, having the benefit of the teaching presented in the foregoing description and associated drawings. It is thus understood that the disclosure is not limited to the specific aspects disclosed hereinabove, and that many modifications and other aspects are intended to be included within the scope of the appended claims. Moreover, although specific terms are employed herein, as well as in the claims that follow, they are used only in a generic and descriptive sense, and not for the purposes of limiting the described disclosure.
The present application is a continuation-in-part of and claims the benefit of U.S. patent application Ser. No. 17/931,078, filed Sep. 9, 2022, which claims the benefit of U.S. Provisional Patent Application No. 63/261,054, filed Sep. 9, 2021, U.S. Provisional Patent Application No. 63/261,748, filed Sep. 28, 2021, U.S. Provisional Patent Application No. 63/261,750, filed Sep. 28, 2021, U.S. Provisional Patent Application No. 63/261,753, filed Sep. 28, 2021, U.S. Provisional Patent Application No. 63/261,757, filed Sep. 28, 2021, U.S. Provisional Patent Application No. 63/264,525, filed Nov. 24, 2021, U.S. Provisional Patent Application No. 63/264,527, filed Nov. 24, 2021, U.S. Provisional Patent Application No. 63/264,529, filed Nov. 24, 2021, U.S. Provisional Patent Application No. 63/264,535, filed Nov. 24, 2021, U.S. Provisional Patent Application No. 63/264,537, filed Nov. 24, 2021, U.S. Provisional Patent Application No. 63/269,936, filed Mar. 25, 2022, and U.S. Provisional Patent Application No. 63/269,938, filed Mar. 25, 2022, the entire contents of each of which are incorporated herein by reference as if repeated in their entirety herein.
| Number | Date | Country | |
|---|---|---|---|
| 63269938 | Mar 2022 | US | |
| 63261054 | Sep 2021 | US | |
| 63261748 | Sep 2021 | US | |
| 63261750 | Sep 2021 | US | |
| 63261753 | Sep 2021 | US | |
| 63261757 | Sep 2021 | US | |
| 63264527 | Nov 2021 | US | |
| 63264529 | Nov 2021 | US | |
| 63264535 | Nov 2021 | US | |
| 63264537 | Nov 2021 | US | |
| 63269936 | Mar 2022 | US |
